appScorecard
Performance
LowHasn't faired well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
News & Opinions
Sakar Healthcare consolidated net profit declines 21.14% in the September 2022 quarter
5 months ago•Business Standard
Sakar Healthcare standalone net profit declines 93.89% in the December 2021 quarter
1 year ago•Business Standard
Sakar Healthcare standalone net profit declines 46.05% in the September 2021 quarter
1 year ago•Business Standard
Sakar Healthcare’s fully-integrated anti-cancer formulation unit now starts with Research Lab; Stock ends 2% up
1 year ago•India Infoline
Sakar Healthcare standalone net profit rises 40.93% in the June 2021 quarter
1 year ago•Business Standard
Swiss-based HBM Healthcare invests Rs14.85cr in Sakar Healthcare through COBRA wing
1 year ago•India Infoline
BRIEF-Sakar Healthcare Says HBM Healthcare Investments Invested 148.5 Mln Rupees In Co
1 year ago•Investing.com